MA28146A1 - Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique - Google Patents

Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique

Info

Publication number
MA28146A1
MA28146A1 MA28995A MA28995A MA28146A1 MA 28146 A1 MA28146 A1 MA 28146A1 MA 28995 A MA28995 A MA 28995A MA 28995 A MA28995 A MA 28995A MA 28146 A1 MA28146 A1 MA 28146A1
Authority
MA
Morocco
Prior art keywords
induced
methods
exercise
preventing
jtv
Prior art date
Application number
MA28995A
Other languages
English (en)
Inventor
Andrew Robert Marks
Donald W Landry
Shi Xian Deng
Zhen Zhuang Cheng
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MA28146A1 publication Critical patent/MA28146A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Cette invention concerne un procédé visant à limiter ou à prévenir une baisse du niveau de protéines FKBP12.6 liées à RyR2 chez un sujet, une méthode de traitement ou de prévention de l'arythmie cardiaque induite par l'exercice physique chez un sujet, ainsi qu'une méthode de prévention de la mort cardiaque subite induite par l'exercice physique chez un sujet. Cette invention concerne également les utilisations de JTV-519 dans ces méthodes. Cette invention concerne en outre des méthodes permettant d'identifier des agents utilisés pour prévenir la mort cardiaque subite induite par l'exercice physique, ainsi que les agents identifiés par ces méthodes. Cette invention concerne par ailleurs des méthodes de prévention de la mort cardiaque subite induite par l'exercice physique consistant à administrer ces agents. En outre, cette invention concerne des méthodes permettant de synthétiser le JTV-519, le JTV-519 radio marqué et des intermédiaires et dérivés de la 1,4-benzothiazépine.
MA28995A 2003-10-07 2006-05-02 Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique MA28146A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/680,988 US20040229781A1 (en) 2000-05-10 2003-10-07 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias

Publications (1)

Publication Number Publication Date
MA28146A1 true MA28146A1 (fr) 2006-09-01

Family

ID=34465444

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28995A MA28146A1 (fr) 2003-10-07 2006-05-02 Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique

Country Status (14)

Country Link
US (1) US20040229781A1 (fr)
EP (1) EP1684735A4 (fr)
JP (1) JP2007507536A (fr)
KR (1) KR20060110290A (fr)
CN (1) CN100502845C (fr)
AU (1) AU2004281672A1 (fr)
BR (1) BRPI0415434A (fr)
CA (1) CA2541847A1 (fr)
EA (1) EA011357B1 (fr)
MA (1) MA28146A1 (fr)
NO (1) NO20062063L (fr)
SG (1) SG147414A1 (fr)
WO (1) WO2005037195A2 (fr)
ZA (1) ZA200603593B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2006028863A1 (fr) * 2004-09-01 2006-03-16 Nexmed Holdings, Inc. Systeme d'administration transdermique d'une composition antiemetique
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008140592A2 (fr) * 2006-11-29 2008-11-20 Armgo Pharma, Inc. 1,4-benzothiazépines radioactivement marquées et procédés de criblage de composés qui lient les récepteurs de la ryanodine
AU2009221969B2 (en) * 2008-03-03 2012-04-19 Rycarma Therapeutics, Inc. Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
WO2010120382A1 (fr) 2009-04-15 2010-10-21 State Of Oregon By And Through The State Board Of Higher Education On Behalf Of Portland State University Composés et procédés de modulation de l'activité des canaux de libération de calcium
EP2708535A1 (fr) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
EP4433062A4 (fr) * 2021-11-16 2025-10-22 Rycarma Therapeutics Inc Composés thérapeutiques

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) * 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
EP0150996B1 (fr) * 1984-01-27 1988-01-07 Ajinomoto Co., Inc. Préparation des dérivés d'acide heptanoique
US4841055A (en) * 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
US4723012A (en) * 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5124056A (en) * 1987-07-24 1992-06-23 Exxon Chemical Patents Inc. Polymer substituted amido-amine Mannich Base lubricant dispersant additives
JPS6445706A (en) * 1987-08-17 1989-02-20 Sumitomo Electric Industries Production of composite carbon nitride
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
EP0368063B1 (fr) * 1988-11-05 1992-06-10 Bayer Ag Procédé pour la chlorination dans le noyau d'hydrocarbures aromatiques
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
EP0446374B1 (fr) * 1989-09-30 1996-02-07 Kirin Beer Kabushiki Kaisha Procede de production de plants
KR940000166B1 (ko) * 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US5204462A (en) * 1990-03-30 1993-04-20 Japan Tobacco, Inc. 4h-3,1-benzoxazin-4-one derivative
US5517652A (en) * 1990-05-30 1996-05-14 Hitachi, Ltd. Multi-media server for treating multi-media information and communication system empolying the multi-media server
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
EP0638560A4 (fr) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical Medicament utilise pour traiter l'osteoporose et compose de diazepine.
AU3143593A (en) * 1991-12-20 1993-07-28 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin E2 antagonists
MX9300433A (es) * 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
US5387684A (en) * 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
WO1994001409A1 (fr) * 1992-07-02 1994-01-20 Fujisawa Pharmaceutical Co., Ltd. Nouvel intermediaire pour la synthese et la production d'un derive d'aminoacide
WO1994004523A1 (fr) * 1992-08-21 1994-03-03 Japan Tobacco Inc. Compose dioxacycloalcane a activite inhibitrice de la renine
RU2115650C1 (ru) * 1992-11-09 1998-07-20 Дзе Бутс Компани ПЛС 2,3,4,5-тетрагидро-1,4-бензотиазепины, их стереоизомеры или их фармацевтически приемлемые соли, способ их получения, фармацевтическая композиция, обладающая противосудорожным действием
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
US5719155A (en) * 1993-11-10 1998-02-17 Japan Tobacco Inc. Chroman derivative and pharmaceutical use thereof
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) * 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
WO1995034642A1 (fr) * 1994-06-15 1995-12-21 Kirin Beer Kabushiki Kaisha Nouvelles transferase et amylase, procede de production de ces enzymes, utilisation, et genes les codant
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
CA2259922C (fr) * 1996-07-08 2009-04-28 Kirin Beer Kabushiki Kaisha Composes actifs comme recepteurs du calcium
US5785178A (en) * 1996-11-04 1998-07-28 Minnesota Mining And Manufacturing Co. Packaged photocurable composition
ATE290068T1 (de) * 1996-12-12 2005-03-15 Kirin Brewery Beta 1-4 n-acetylglucosaminyltransferase sowie das für diese kodierende gen
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
EP0965840A4 (fr) * 1997-10-08 2001-10-31 Noboru Kaneko Procede d'analyse de l'annexine v dans l'urine et utilisation
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
WO1999033878A1 (fr) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
RU2202344C2 (ru) * 1998-03-26 2003-04-20 Джапан Тобакко Инк. Антагонисты ноцицептина, производные амида, аналгетик, способ инициирования антагонистического действия к ноцицептину, способ лечения боли, фармацевтические композиции
EP1070714B1 (fr) * 1998-04-10 2004-08-04 Japan Tobacco Inc. Composes d'amidine
WO1999064045A1 (fr) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Agents therapeutiques agissant sur les transporteurs membranaires
AU4930299A (en) * 1998-07-31 2000-02-21 Kirin Beer Kabushiki Kaisha Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives
DE69929362T2 (de) * 1998-12-28 2006-09-28 Kaneko, Noboru verwendung von 1,4-benzothiazepinen zur Herstellung eines Medikaments ZUR BEHANDLUNG DER VORHOF-FIBRILLATION
EP1167537B1 (fr) * 1999-03-30 2008-07-23 Japan Tobacco Inc. Procede pour la production d'anticorps monoclonal
WO2001016321A1 (fr) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Adn et sequences proteiniques de glycoproteine vi (gpvi) de membranes plaquettaires et utilisations de ceux-ci
EP1222924B1 (fr) * 1999-09-30 2006-12-27 Noboru Kaneko Agents anticancereux
US6568474B2 (en) * 1999-12-20 2003-05-27 Bj Services, Usa Rigless one-trip perforation and gravel pack system and method
WO2001047510A2 (fr) * 1999-12-29 2001-07-05 Glaxo Group Limited Methodes et compositions liees aux modulateurs de l'annexine et de l'homeostasie cartilagineuse
NZ519981A (en) * 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
KR20020093971A (ko) * 2000-05-03 2002-12-16 워너-램버트 캄파니 울혈성 심부전의 치료
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
WO2002009761A2 (fr) * 2000-07-27 2002-02-07 Pharmacia Corporation Polytherapie par antagoniste d'aldosterone epoxy-steroidien et inhibiteur calcique pour le traitement de l'insuffisance cardiaque congestive
TWI290130B (en) * 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
CA2430013C (fr) * 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
US6673904B2 (en) * 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
EP1365022A4 (fr) * 2001-02-01 2004-04-28 Mochida Pharm Co Ltd Proteine associee a l'adiponectine
JP4817514B2 (ja) * 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
EP1369129A4 (fr) * 2001-03-14 2005-08-03 Ono Pharmaceutical Co Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
WO2002088110A1 (fr) * 2001-04-27 2002-11-07 Kirin Beer Kabushiki Kaisha Derives de quinoline ayant un groupe azolyle et derives de quinazoline
BR0212512A (pt) * 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
JP2003145746A (ja) * 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
JPWO2003043655A1 (ja) * 2001-11-19 2005-03-10 小野薬品工業株式会社 頻尿の治療剤
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
BR0306643A (pt) * 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
EP1557099A1 (fr) * 2002-04-26 2005-07-27 Japan Tobacco Inc. Dispositif de fabrication d'articles en forme de barre
JP4113042B2 (ja) * 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
PT1533292E (pt) * 2002-08-30 2007-05-31 Japan Tobacco Inc Compostos de dibenzilamina e sua utilização farmacêutica.
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20050009733A1 (en) * 2003-04-22 2005-01-13 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005016249A2 (fr) * 2003-07-11 2005-02-24 Pharmacia Corporation Compositions constituees d'un inhibiteur chromene ou acide phenylacetique selectif de la cyclooxygenase-2 et d'un inhibiteur de ace pour traiter les lesions du systeme nerveux central
EP1653969A4 (fr) * 2003-08-07 2006-12-20 Japan Tobacco Inc Derives de pyrrolo 1,2-b pyridazine
EP1670459A4 (fr) * 2003-08-20 2009-03-25 Nitromed Inc Composes cardiovasculaires nitroses et nitrosyles, compositions et procedes d'utilisation
US20070238740A1 (en) * 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
EP1749102A4 (fr) * 2004-04-22 2009-02-25 Kirin Pharma Kk Animaux transgeniques et leurs utilisations
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) * 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
SG147414A1 (en) 2008-11-28
CN100502845C (zh) 2009-06-24
EP1684735A2 (fr) 2006-08-02
US20040229781A1 (en) 2004-11-18
EA011357B1 (ru) 2009-02-27
ZA200603593B (en) 2010-10-27
WO2005037195A2 (fr) 2005-04-28
EA200600740A1 (ru) 2006-10-27
WO2005037195A3 (fr) 2005-12-01
JP2007507536A (ja) 2007-03-29
CA2541847A1 (fr) 2005-04-28
KR20060110290A (ko) 2006-10-24
CN1886122A (zh) 2006-12-27
NO20062063L (no) 2006-07-07
BRPI0415434A (pt) 2006-12-05
EP1684735A4 (fr) 2009-01-07
AU2004281672A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
MA28146A1 (fr) Composes et methodes de traitement et de prevention d'arythmies cardiaques induites par l'exercice physique
WO2004027027A3 (fr) Methode d'inhibition de la neovascularisation choroidienne
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA31766B1 (fr) Composés organiques
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA30440B1 (fr) NOUVEAUX MEDICAMENTS ANTIARYTHMIQUES ET CONTRE LA DEFAILLANCE CARDIAQUE CIBLANT LA FUITE DANS UN RECEPTEUR DE LA PYANODINE (RyR2).
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
WO2006028957A8 (fr) Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA31276B1 (fr) Amides substitués, procédé de production et d'utilisation desdits amides.
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA29326B1 (fr) Combinaison de composes organiques
MA31001B1 (fr) Quinazolines destines a l'inhibition de pdk
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
EA200001085A1 (ru) 5-аминоиндено [1, 2-с]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
MA27775A1 (fr) Composes organiques
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
TN2009000018A1 (fr) Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue